-
公开(公告)号：KR100834026B1
公开(公告)日：2008-06-02
申请号：KR1020070001888
申请日：2007-01-08
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
CPC classification number: A61K39/0208 , C07K14/195
Abstract: A riemerella vaccine for preventing riemerella infection is provided to defend the infection of field pathogenic Riemerella anatipestifer which occurs frequently in a country and prevent ducks from being perished by the riemerella infection, thereby minimizing economical loss of a duck industry. A riemerella vaccine for preventing riemerella infection comprises an inactivated Riemerella anatipestifer and an immuno-enhancing agent, wherein the inactivated Riemerella anatipestifer is a strain selected from the group consisting of serovar type I, serovar type IV, serovar type VII, serovar type XVI and a mixture strain thereof. A method for preparing the riemerella vaccine comprises the steps of: (a) culturing Riemerella anatipestifer isolated from a suck; (b) adding an inactivating agent such as 0.3% formalized physiological saline solution(FPSS) to a culture solution obtained from the step(a) to inactivate the Riemerella anatipestifer; and (c) adding an immuno-enhancing agent to the inactivated Riemerella anatipestifer culture solution to prepare a mixture vaccine. Further, the immuno-enhancing agent is ISA70.
Abstract translation: 提供了一种用于预防痢疾杆菌感染的雷米他菌疫苗，用于捍卫一个国家频繁发生的野外致病性雷米他氏菌感染，并防止鸭子被莱梅里埃菌感染消灭，从而最大限度地减少了鸭业的经济损失。 用于预防雷米他里亚感染的莱米诺菌素疫苗包括灭活的雷米他氏菌和免疫增强剂，其中所述灭活的雷米他氏菌是选自I型血清型，IV型血清型，VII型血清型，血清型XVI和 其混合应变。 一种制备莱米酵母疫苗的方法包括以下步骤：（a）培养从吸吮物分离的烟草雷蒙酵母; （b）将灭活剂如0.3％正规化生理盐水溶液（FPSS）加入到从步骤（a）获得的培养溶液中以灭活烟草雷蒙酵母; 和（c）向灭活的雷神雷公藤培养液中加入免疫增强剂以制备混合疫苗。 此外，免疫增强剂是ISA70。
-
公开(公告)号：KR100790801B1
公开(公告)日：2008-01-04
申请号：KR1020050060920
申请日：2005-07-06
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
Abstract: 본 발명은 HA 단백질 분절부위 아미노산 배열의 모티프가 TSGR을 가지며, 국내유행 저병원성 조류인플루엔자 바이러스에 방어능력을 나타내는 백신제조용 H9N2 혈청형의 저병원성 조류인플루엔자 바이러스주를 제공한다. 상기 바이러스주를 백신제조용 원료로 사용하는 경우 양계산업에 있어 산란율 저하 및 폐사 등 지속적인 문제를 일으키는 H9N2 혈청형 저병원성 조류인플루엔자 예방에 활용이 가능하다.
저병원성 조류인플루엔자, H9N2, 백신-
公开(公告)号：KR1020070121468A
公开(公告)日：2007-12-27
申请号：KR1020060056569
申请日：2006-06-22
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
IPC: C12Q1/68
CPC classification number: C12N15/11 , C12Q1/686 , G01N33/569
Abstract: A differential diagnostic method of duck hepatitis virus(DHV) type 1 is provided to improve rapidness and accuracy of diagnosis, and diagnose common genes and different genes of duck hepatitis virus type 1 in the liver tissue separated from young ducks infected by the duck hepatitis virus type 1, and viruses causing other RNA viral diseases derived from fowls. Duck hepatitis virus type 1 gene has the nucleotide sequence consisting of 2C gene, capsid gene and 5'-UTR(untranslated region) gene, wherein the 2C gene has the nucleotide sequence selected from SEQ ID NOs:1, 4, 7, 10, 13, 16, 19, 22 and 25; the capsid gene has the nucleotide sequence selected from SEQ ID NOs:2, 5, 8, 11, 14, 17, 20, 23 and 26; and the 5'-UTR gene has the nucleotide sequence selected from SEQ ID NOs:3, 6, 9, 12, 15, 18, 21, 24 and 27. Duck hepatitis virus-specific primers have the nucleotide sequences of SEQ ID NOs:28 to 33 and specifically recognize the 2C gene, capsid gene and 5'-UTR gene, respectively. A differential diagnostic method of duck hepatitis virus(DHV) type 1 comprises the steps of: (1) homogenizing the liver tissue separated from young ducks infected by the duck hepatitis virus type 1 to float in 10% PBS(phosphate buffered saline); (2) obtaining the supernatant and separating RNA from the supernatant by RNA extraction method; (3) synthesizing cDNA(complementary DNA) from the separated RNA through reverse transcription method by using reverse transcriptase; (4) preparing primers specific to 2C gene, capsid gene and 5'-UTR gene from cDNA, and amplifying the genes through PCR(polymerase chain reaction); and (5) subjecting the PCR products to electrophoresis using 1.5% agarose gel.
Abstract translation: 提供1型鸭肝炎病毒（DHV）的鉴别诊断方法，以提高诊断的快速性和准确性，并在鸭肝炎病毒感染的幼鸭分离的肝组织中诊断1型鸭肝炎病毒的常见基因和不同基因 类型1，以及导致其他来源于家禽的RNA病毒病毒的病毒。 鸭肝炎病毒1型基因具有由2C基因，衣壳基因和5'-UTR（非翻译区）基因组成的核苷酸序列，其中2C基因具有选自SEQ ID NO：1,4,7,10， 13，16，19，22和25; 所述衣壳基因具有选自SEQ ID NO：2,5,8,11,14,17,20,23和26的核苷酸序列; 并且5'-UTR基因具有选自SEQ ID NO：3,6,9,12,15,18,21,24和27的核苷酸序列。鸭肝炎病毒特异性引物具有SEQ ID NO： 28〜33，分别特异性地识别2C基因，衣壳基因和5'-UTR基因。 鸭肝炎病毒（DHV）1型的鉴别诊断方法包括以下步骤：（1）将由1型鸭肝炎病毒感染的幼鸭分离的肝组织匀浆在10％PBS（磷酸盐缓冲盐水）中漂浮; （2）通过RNA提取方法获得上清液和上清液中的RNA; （3）使用逆转录酶通过逆转录法从分离的RNA合成cDNA（互补DNA）; （4）从cDNA制备特异于2C基因，衣壳基因和5'-UTR基因的引物，并通过PCR（聚合酶链式反应）扩增基因; 和（5）使用1.5％琼脂糖凝胶对PCR产物进行电泳。
-
公开(公告)号：KR100664995B1
公开(公告)日：2007-01-04
申请号：KR1020060002630
申请日：2006-01-10
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
Abstract: A method for diagnosing duck hepatitis virus type 1 is provided to reduce the diagnosis time, improve convenience of diagnosis, and enhance diagnosis accuracy by performing PCR using a primer set specific to duck hepatitis virus type 1. The method for diagnosing duck hepatitis virus type 1 comprises the steps of: (1) pulverizing the liver tissue infected by duck hepatitis virus and suspending the pulverized liver tissue in PBS(phosphate buffer saline); (2) extracting RNA from the supernatant by using LS reagent; (3) synthesizing cDNA from the extracted RNA by using reverse transcriptase(MMLV); (4) performing PCR using synthesized cDNA as a template using 3D gene-specific primers having the nucleotide sequences of SEQ ID NOs:6 and 7; and (5) subjecting the PCR product to electrophoresis by using 1.5% agarose gel, wherein the 3D gene is derived from duck hepatitis virus type 1 and has the nucleotide sequence selected from SEQ ID NO:1 to SEQ ID NO:5.
Abstract translation: 提供一种用于诊断1型鸭肝炎病毒的方法，通过使用特异于1型鸭肝炎病毒的引物组进行PCR，减少诊断时间，提高诊断方便性，提高诊断准确度。1型鸭肝炎病毒诊断方法 包括以下步骤：（1）粉碎鸭肝炎病毒感染的肝组织，并将粉碎的肝组织悬浮于PBS（磷酸盐缓冲盐水）中; （2）使用LS试剂从上清液中提取RNA; （3）使用逆转录酶（MMLV）从提取的RNA合成cDNA; （4）使用具有SEQ ID NO：6和7的核苷酸序列的3D基因特异性引物，使用合成的cDNA作为模板进行PCR; 和（5）使用1.5％琼脂糖凝胶对PCR产物进行电泳，其中3D基因来源于1型鸭型肝炎病毒，并具有选自SEQ ID NO：1至SEQ ID NO：5的核苷酸序列。
-
公开(公告)号：KR1020060132155A
公开(公告)日：2006-12-21
申请号：KR1020050052325
申请日：2005-06-17
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
IPC: A61K39/145 , A61K39/12
CPC classification number: A61K39/145 , A61K38/02 , Y10S514/888
Abstract: A low pathogenic avian influenza viral vaccine for preventing H5 subtype avian influenza viral infection is provided to enhance safety and medicinal efficacy of use, and prevent the infection of H5N1 type high pathogenic avian influenza virus safely. The method for preparing the low pathogenic avian influenza viral vaccine for preventing H5 subtype avian influenza viral infection comprises the steps of: (1) culturing a A/wild bird feces/Korea/CSM-2/02(H5N3) strain in a specific pathogen free egg(SPF egg) for 72 hours and collecting allantoic fluid; (2) measuring the titrate of the virus collected in step(1) through hemagglutination inhibition test; (3) concentrating the virus 10 times by centrifuging the virus at 18,000 rpm for 3 hours; (4) attenuating the virus by treating the concentrated virus with 0.1% formalin at 20 deg.C for 12 hours; and (5) mixing the attenuated virus solution with oil adjuvant ISA70 in a weight ratio of 3:7, wherein the low pathogenic avian influenza viral vaccine contains at least one protein encoded by the gene of SEQ ID NO:2 to SEQ ID NO:9.
Abstract translation: 提供用于预防H5亚型禽流感病毒感染的低致病性禽流感病毒疫苗，以提高使用的安全性和药用效力，并安全防止H5N1型高致病性禽流感病毒感染。 制备用于预防H5亚型禽流感病毒感染的低致病性禽流感病毒疫苗的方法包括以下步骤：（1）在特定病原体中培养A /野鸟粪/韩国/ CSM-2/02（H5N3）菌株 免费鸡蛋（SPF蛋）72小时并收集尿囊液; （2）通过血细胞凝集抑制试验测定步骤（1）中收集的病毒的滴度; （3）通过以18,000rpm将病毒离心3小时来浓缩病毒10次; （4）通过用0.1％福尔马林在20℃处理浓缩的病毒12小时来减毒病毒; 和（5）将减毒病毒溶液与油佐剂ISA70以3:7的重量比混合，其中低致病性禽流感病毒疫苗含有由SEQ ID NO：2至SEQ ID NO：2的基因编码的至少一种蛋白质。 9。
-
Patent Agency Ranking
公开(公告)号：KR1020140010583A
公开(公告)日：2014-01-27
申请号：KR1020120076917
申请日：2012-07-13
Applicant: 서울대학교산학협력단 , 대한민국(농림축산식품부 농림축산검역본부장)
IPC: C12N7/01 , C12N15/63 , C12N15/33 , A61K39/145
Abstract: Provided are: a method for improving immunogenicity of a HA2 common epitope of influenza virus by replacing asparagine, which is the 154th amino acid, and serine (S) or threonine (T), which is the 156the amino acid, with other amino acid such that N-glycan generation does not occur at asparagine (N), which is the 154th amino acid, of a HA2 fragment derived from a HA amino acid of avian influenza virus; and a recombinant virus with improved immunogenicity through the method. The technic for improving immunogenicity of a HA2 common epitope and the HA2 common epitope high immunogenicity virus of the present invention can be effectively used in developing a vaccine strain for preventing influenza and effectively used as a vaccine strain.
Abstract translation: 提供：通过将作为第154位氨基酸的天冬酰胺和作为氨基酸的156位的丝氨酸（S）或苏氨酸（T）与其它氨基酸这样的氨基酸取代来改善流感病毒的HA2常见表位的免疫原性的方法 来自禽流感病毒的HA氨基酸的HA2片段的第155位氨基酸的天冬酰胺（N）不发生N-聚糖生成; 和通过该方法具有改善的免疫原性的重组病毒。 用于提高本发明的HA2常见表位和HA2常见表位高免疫原性病毒的免疫原性的技术可以有效地用于开发用于预防流行性感冒并有效用作疫苗株的疫苗株。
-
公开(公告)号：KR1020140010582A
公开(公告)日：2014-01-27
申请号：KR1020120076916
申请日：2012-07-13
Applicant: 서울대학교산학협력단 , 대한민국(농림축산식품부 농림축산검역본부장)
Abstract: The present invention relates to: a composition for high productiveness of an embryonated egg of H1N1 family avian influenza and non-pathogenicity of a mouse including, as a active ingredient, a polynucleotide encoding a PB2 protein of a low pathogenic avian influenza virus; a recombinant expression vector including the polynucleotide; an attenuated recombinant virus transformed into the expression vector; and a vaccine composition including the recombinant expression vector. The recombinant expression vector of the present invention enhances chicken embryo productivity of a vaccine strain for preventing influenza, and thereby, having advantages of being capable of being effectively used in enhancing efficacy and productivity of killed vaccines, and additionally, has no pathogenicity for mice and has immunogenicity, and thereby having advantages of being capable of being effectively used as live vaccines. [Reference numerals] (AA) Inserting into the inside of pHW2000-BsmBI
Abstract translation: 本发明涉及一种用于H1N1家禽禽流感的胚胎卵和非致病性的高生产力的组合物，其包含作为活性成分的编码低致病性禽流感病毒的PB2蛋白的多核苷酸; 包含该多核苷酸的重组表达载体; 减毒的重组病毒转化成表达载体; 以及包含重组表达载体的疫苗组合物。 本发明的重组表达载体增强用于预防流感的疫苗株的鸡胚生产力，从而具有能够有效地用于提高杀死疫苗的功效和生产力的优点，此外，对小鼠没有致病性， 具有免疫原性，因此具有能够有效地用作活疫苗的优点。 （标号）（AA）插入pHW2000-BsmBI的内部
-
8.发明授权신속 면역크로마토그라피법에 의한 Ｈ5형 고병원성 및 일반조류인플루엔자 바이러스 항원 진단 스트립 및 그 제조방법 有权H5型高致病性禽流感病毒抗原诊断条和使用快速免疫色谱法的一般禽流感病毒抗原及其制备方法
公开(公告)号：KR100762825B1
公开(公告)日：2007-10-04
申请号：KR1020060000325
申请日：2006-01-03
Applicant: 대한민국(농림축산식품부 농림축산검역본부장) , 주식회사 바이오노트
IPC: G01N33/53
Abstract: 본 발명은 신속 면역크로마토그라피법 (rapid immunochromatography)에 의한 일반 조류인플루엔자 및 H5형 고병원성 조류인플루엔자 진단 스트립 및 그 제조 방법에 관한 발명으로 상세하게는 헤마글루티닌 항원이 H1형부터 H15형인 모든 조류 인플루엔자 바이러스에 공통적인 항체 및 헤마글루티닌 항원이 H5인 고병원성 조류인플루엔자에 특이적인 항체를 사용하여 신속 면역크로마토그라피법에 의해 조류 분변 또는 조직에서 일반 조류인플루엔자 바이러스 및 H5인 고병원성 조류인플루엔자 감염여부를 신속하고 감별적으로 검사할 수 있는 진단 스트립 및 그 제조 방법에 관한 것이다.
고병원성 조류 인플루엔자, 신속 면역크로마토그라피법, 헤마글루티닌, 뉴클레오프로테인-
公开(公告)号：KR100693858B1
公开(公告)日：2007-03-14
申请号：KR1020050052325
申请日：2005-06-17
Applicant: 대한민국(농림축산식품부 농림축산검역본부장)
IPC: A61K39/145 , A61K39/12
Abstract: 본 발명은 동물 또는 사람에서 H5 혈청형 고병원성 조류인플루엔자 바이러스 감염을 예방하기 위하여, 상기 고병원성 조류인플루엔자 바이러스와 방어 혈청형이 같으면서 병원성이 없는 야생 철새에서 분리된 H5N3 혈청형 조류인플루엔자 바이러스를 이용하여 제조한 백신주에 관한 것이다.
조류인플루엔자, H5N3 조류인플루엔자 바이러스, H5 고병원성 조류인플루엔자 바이러스, 백신, 백신주-
10.发明授权뉴캣슬병 바이러스 검출 및 병원성 진단용 프라이머 및상기 프라이머를 포함하는 뉴캣슬병 바이러스 검출 및병원성 진단용 킷트 有权新城疫病毒检测和致病性检测用引物，以及包含上述引物的新城疫病毒检测和致病性诊断试剂盒
公开(公告)号：KR100451883B1
公开(公告)日：2004-10-08
申请号：KR1020030088228
申请日：2003-12-05
Applicant: 주식회사 인트론바이오테크놀로지 , 대한민국(농림축산식품부 농림축산검역본부장)
IPC: C12N15/45
Abstract: PURPOSE: A primer and kit for detection and pathotype-diagnosis of Newcastle disease virus are provided, thereby simultaneously detecting the Newcastle disease virus and diagnosing pathotype of the Newcastle disease virus, so that death rate of domestic animals by the Newcastle disease virus can be reduced. CONSTITUTION: The primer for detection and pathotype-diagnosis of Newcastle disease virus is selected from a primer set having the nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:2, a primer set having the nucleotide sequences of SEQ ID NO:2 and SEQ ID NO:3, and a primer set having the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. The method for pathotype-diagnosis of Newcastle disease virus comprises the steps of: (1) obtaining RNA from a sample; (2) carrying out reverse transcription of the RNA to obtain cDNA; (3) PCR amplifying the cDNA using the primer; (4) subjecting the PCR product to electrophoresis; and (5) deciding the Newcastle disease virus as non-pathogenic virus when the PCR product shows a band of 379bp, or as pathogenic virus when the PCR product shows two bands of 379bp and 204bp.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.04 seconds)
